Phase 3 Start

SMMT: Phase3_Start: A Randomized Phase 2/3 Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (HARMONi-GU1)

Name: Phase3_Start: A Randomized Phase 2/3 Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (HARMONi-GU1)
Start: 2026-09-10
End: 2026-09-10

September 10, 2026 · started. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: September 10, 2026
Company: Summit Therapeutics Inc. (SMMT)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Startstarted

Phase3_Start: A Randomized Phase 2/3 Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (HARMONi-GU1)

September 10, 2026

SMMT overview →

Company: Summit Therapeutics Inc. (SMMT)

Other upcoming events for SMMT

PDUFA DatePDUFA: ivonescimab

Nov 14, 2026